Market Definition
Infectious respiratory diseases are generally caused by the spread of bacteria, viruses, or other pathogenic microbes through saliva & mucus when a person talks, sneezes, coughs, or even laughs, which can severely infect the respiratory system of an individual. With the growing cases of such diseases worldwide, especially among the elderly population, early & accurate diagnosis of the disease-causing pathogens is becoming increasingly crucial for administering appropriate therapies, initiating effective infection control measures, and minimizing the length of hospital stay. As a result, significant R&D investments are being directed toward introducing novel diagnostics & therapeutics to treat patients with infectious respiratory diseases.
Market Insights
The Global Infectious Respiratory Disease Diagnostics Market is expected to grow at a considerable CAGR during the forecast period, i.e., 2023-28. Respiratory infectious diseases like pneumonia, bronchitis, sinus infections, and laryngitis, among others, are the third leading cause of death and result in over 3 million deaths every year globally, cites WHO. The mounting prevalence of these illnesses owing to changing lifestyles, increasing adoption of advanced molecular therapeutics, rapidly rising elderly population, and various initiatives taken by governments & non-profit organizations across different countries worldwide toward minimizing the incidence of these diseases are the prime aspects projected to drive the Infectious Respiratory Disease Diagnostics Market through 2028.
| Report Coverage | Details |
|---|---|
| Study Period | Historical Data: 2018-21 |
| Base Year: 2022 | |
| Forecast Period: 2023-28 | |
| Regions Covered | North America: USA, Canada, Mexico |
| South America: Brazil, Argentina, Rest of South America | |
| Europe: The UK, Germany, France, Spain, Italy, Rest of Europe | |
| Asia-Pacific: China, India, Japan, South Korea, Australia, Singapore, Rest of Asia-Pacific | |
| Middle East & Africa: Saudi Arabia, UAE, South Africa, Rest of Middle East & Africa | |
| Key Companies Profiled | Abacus Diagnostica Oy, Abbott Laboratories, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), Biocartis, bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher, F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Illumina, Inc., QIAGEN N.V., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., PerkinElmer, Inc., Hologic Inc., Novacyt Group, Qiagen, Quidel Corporation, Seegene, Inc., SDI Diagnostics |
| Unit Denominations | USD Million/Billion |
More and more diagnostics kits, assays, tubes, reagents, & other consumables are being utilized increasingly owing to the growing cancer incidence worldwide. Healthcare firms are substantially investing in introducing new products for infectious respiratory disease diagnostics, as well as in the commercialization of multiplex tests for the simultaneous diagnosis of Respiratory Syncytial Virus (RSV), Covid-19, & influenza, as these illnesses have similar symptoms.
As multiplex testing allows for the simultaneous targeting of multiple genes, which helps minimize the time & cost incurred with traditional diagnostics, such as PCR, the need for its global commercialization is accelerating at a phenomenal pace. Additionally, the launch of new molecular diagnostic tests for SARS-CoV-2 detection, increasing utilization of self-test kits & point-of-care products, as well as rapid technological advancements that have enabled accurate, portable, & cost-effective diagnostics are other crucial aspects projected to stimulate the expansion of the Global Infectious Respiratory Disease Diagnostics Market over the coming years.
Market Segmentation
Based on Product Type:
Of these three, consumables dominated the Global Infectious Respiratory Disease Diagnostics Market. The same trend is likely over the coming few years, owing mainly to increased testing rates worldwide due to the ongoing pandemic. Consumables include assays & reagents that are used for performing IVD (In-vitro Diagnostic) tests for respiratory diseases and help significantly reduce ambiguity by providing reliable outcomes. As a result, the globally rising cases of infectious diseases and growing awareness among individuals of the importance of early disease detection in less time & costs shall continue promulgating the demand for consumables and, in turn, drive the Global Infectious Respiratory Disease Diagnostics Market through 2028.
Based on Sample Type:
Here, Nasopharyngeal Swabs (NPS) dominated the market with the largest share in the previous years. It owes mainly to the advent of Covid-19 in 2020, which enabled an extensive utilization of NPS for conducting various tests, including but not limited to rapid antigen detection, direct fluorescent antibodies, and PCR (Polymerase Chain Reaction), among others.
Undoubtedly, the pandemic has acted as the most prominent driving factor for NPS use across different countries worldwide, mainly due to the mandatory Covid-19 mass testing of individuals for travel & safety purposes. Several companies have exponentially increased their swab production & distribution capacities in order to cater to the heightened consumer demands. Until the entire global population gets vaccinated, NPS demand is expected to remain at its peak.
Hence, the mounting incidence of zoonotic diseases like MERS & SARD that severely affect the respiratory organs of individuals shall continue to augment the demand for NPS and, consequently, propel the growth of the Global Infectious Respiratory Disease Diagnostics Market in the coming years.
Regional Projection
Geographically, the Global Infectious Respiratory Disease Diagnostics Market expands across:
Of all regions globally, Asia-Pacific is expected to attain a significant share of the Infectious Respiratory Disease Diagnostics Market during 2023-28. It owes to the mounting prevalence of respiratory illnesses like COPD (Chronic Obstructive Pulmonary Disease), tuberculosis, asthma, & sleep apnea, among others, coupled with ever-increased pollution levels, the rapidly surging tobacco consumption, increasing number of private-sector healthcare facilities, and rising elderly population levels.
Moreover, the growing affordability of people for advanced diagnostics, massive investments in healthcare infrastructure enhancements, increasing urbanization, active government efforts toward improving the availability of effective diagnostics for patients, burgeoning focus on improving screening rates, and growing applications in home care settings are other prominent aspects projected to stimulate regional market growth in the coming years.
Key Questions Answered in the Market Research Report:
Frequently Asked Questions
A. The Infectious Respiratory Disease Diagnostics Market is projected to register a considerable CAGR during 2023-28.
A. The rising incidence of respiratory diseases worldwide, mounting adoption of advanced molecular techniques, and the increasing focus of both governments & non-profit firms toward minimizing the prevalence of these illnesses are the prime aspects expected to drive the Infectious Respiratory Disease Diagnostics Market during 2023-28.
A. Abacus Diagnostica Oy, Abbott Laboratories, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), Biocartis, bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher, F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Illumina, Inc., QIAGEN N.V., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., PerkinElmer, Inc., Hologic Inc., Novacyt Group, Qiagen, Quidel Corporation, Seegene, Inc., and SDI Diagnostics are the key companies operating in the Infectious Respiratory Disease Diagnostics Market.
A. Consumables would continue generating profitable opportunities for the leading players in the Infectious Respiratory Disease Diagnostics Market during 2023-28.
A. Globally, Asia-Pacific would provide lucrative prospects for the Infectious Respiratory Disease Diagnostics Market in the years ahead.
